Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.
Sep 10, 2024•9 min•Ep. 322
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.
Speaker 3: (00:32)
Would you tell us a little bit about yourself and your history with this testing?
Speaker 3: (01:25)
Would you tell us a little more about this assay?
Speaker 3: (04:57)
Which patients should have this testing and when should it be performed?
Speaker 3: (05:30)
What alternative tests exist and how do they compare?
Speaker 3: (06:28)
How are the results used in patient care?
For the best experience, listen in Metacast app for iOS or Android